120 related articles for article (PubMed ID: 1466253)
1. Do estrogens improve bone mineral density in osteoporotic women over age 65?
Marx CW; Dailey GE; Cheney C; Vint VC; Muchmore DB
J Bone Miner Res; 1992 Nov; 7(11):1275-9. PubMed ID: 1466253
[TBL] [Abstract][Full Text] [Related]
2. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
3. Do estrogens improve bone mass in osteoporotic women over ten years of menopause.
Szejnfeld VL; Souen JS; Baracat EC; Atra E; de Lima GR
Sao Paulo Med J; 1994; 112(1):517-21. PubMed ID: 7871318
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
[TBL] [Abstract][Full Text] [Related]
6. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
Reeve J; Davies UM; Hesp R; McNally E; Katz D
BMJ; 1990 Aug; 301(6747):314-8. PubMed ID: 2393738
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women.
Miller PD; Neal BJ; McIntyre DO; Yanover MJ; Anger MS; Kowalski L
Osteoporos Int; 1991 Jun; 1(3):171-6. PubMed ID: 1790405
[TBL] [Abstract][Full Text] [Related]
8. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
[TBL] [Abstract][Full Text] [Related]
9. Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study.
Watts NB; Nolan JC; Brennan JJ; Yang HM;
Menopause; 2000; 7(6):375-82. PubMed ID: 11127759
[TBL] [Abstract][Full Text] [Related]
10. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy.
Haines CJ; Chung TK; Leung PC; Hsu SY; Leung DH
Bone; 1995 May; 16(5):529-31. PubMed ID: 7654468
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.
Wimalawansa SJ
Am J Med; 1995 Jul; 99(1):36-42. PubMed ID: 7598140
[TBL] [Abstract][Full Text] [Related]
12. Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women.
Davas I; Altintas A; Yoldemir T; Varolan A; Yazgan A; Baksu B
Fertil Steril; 2003 Sep; 80(3):536-40. PubMed ID: 12969694
[TBL] [Abstract][Full Text] [Related]
13. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
Grey AB; Cundy TF; Reid IR
Clin Endocrinol (Oxf); 1994 May; 40(5):671-7. PubMed ID: 8013147
[TBL] [Abstract][Full Text] [Related]
14. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
15. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of long-term fluoride and calcium therapy in correcting the deficit of spinal bone density in osteoporosis.
Farley SM; Libanati CR; Odvina CV; Smith L; Eliel L; Wakley GK; Kilcoyne R; Schulz EE; Baylink DJ
J Clin Epidemiol; 1989; 42(11):1067-74. PubMed ID: 2809662
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
Schneider DL; Barrett-Connor EL; Morton DJ
JAMA; 1994 Apr; 271(16):1245-9. PubMed ID: 7848399
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women.
Grey A; Cundy T; Evans M; Reid I
Clin Endocrinol (Oxf); 1996 Mar; 44(3):293-6. PubMed ID: 8729524
[TBL] [Abstract][Full Text] [Related]
19. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF
Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970
[TBL] [Abstract][Full Text] [Related]
20. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
Orr-Walker BJ; Evans MC; Clearwater JM; Horne A; Grey AB; Reid IR
Arch Intern Med; 2000 Jul; 160(14):2161-6. PubMed ID: 10904459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
